FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
From: .google.com The FDA has approved imlunestrant (Inluriyo) plus abemaciclib (Verzenio) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative,...
Zanidatamab regimens improve survival for gastroesophageal cancer
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...
HER2-targeted Therapy for Salivary Gland Cancer
Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...
Second-Line Trastuzumab Deruxtecan Yields 23-Month Progression-Free Survival in Gastroesophageal Cancer
A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...
AI Reads Routine Mammograms to Predict Breast Cancer HER2 Status Without Biopsy
A dual-center study shows that a deep learning radiomics model applied to routine mammograms can noninvasively predict HER2-positive and HER2-low breast cancer status, offering a p...
New Pill Combo Approved For Breast Cancer, Wilserdly, That Stops Responding To Hormone Therapy
TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...
New Pill Combo, Wilserdly + Everolimus, Approved For Breast Cancer That Stops Responding To Hormone Therapy
TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...
<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab]]>
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...
Dallas researchers seeking patients for breast cancer treatment clinical trial
A clinical trial going on now at UT Southwestern Medical Center in Dallas could lead to a new treatment option for some breast cancer patients. And more women are needed as the...
PET Scan Tumor Uptake Predicts 10-Year Survival in Early Breast Cancer
A retrospective study of 332 patients links pretreatment tumor SUVmax on PET/CT to 10-year recurrence-free and overall survival in early-stage ER-positive, HER2-negative breast can...
<![CDATA[FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer]]>
<![CDATA[FDA Approves Tecentriq for Stage III dMMR Colon Cancer]]>
Local Radiotherapy Response Predicts Survival in Advanced Breast Cancer Cohort Study
A retrospective cohort study found that local tumor response following hypofractionated radiotherapy combined with systemic therapy was independently associated with improved survi...
RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...
Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.